Repligen

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration, Process Analytics, and Proteins. The Chromatography product includes a range of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The Process Analytics products complement and support filtration, chromatography and proteins in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins product franchise is represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Repligen (RGEN) reports strong 2022 performance, eyes growth amid challenges

Repligen anticipates a challenging yet optimistic year in 2023, with revenue guidance of $760-800 million and adjusted EPS of $2.61-2.69 per fully diluted share. The company remains focused on organic growth, innovation, and strategic acquisitions to navigate industry headwinds.

Repligen reports Q1 revenue growth, eyes China rebound and new products

Repligen's Q1 2023 performance saw revenue growth but overall revenues declined due to reduced COVID-related demand.
Despite challenges in China and revised guidance, strategic investments and confidence in future growth opportunities remain strong.
The company is focused on new product launches, pricing resilience, and addressing challenges to drive growth and margin improvement.

Repligen faces revenue decline and margin pressure, eyes growth strategies

Repligen faces challenges in revenue decline and margin compression but is focusing on cost control and new product launches for growth.
Diversified revenue streams and positive developments in orders and integration provide a foundation for future opportunities.
Market dynamics and pharma spend challenges pose uncertainties, but the company remains optimistic about growth prospects.
Visibility improvements, margin recovery expectations, and pricing strategies are key focus areas for future profitability.

Repligen sees recovery in Q3 amidst industry challenges and restructuring

Repligen's Q3 2023 showed signs of recovery amidst industry challenges, with a focus on cost optimization and new product launches. The company incurred restructuring charges to streamline operations and expects improved margins in 2024. Despite revenue declines, opportunities lie in the gene therapy segment and future recovery in China.

Repligen reports Q4 revenue decline but eyes growth in China

Repligen's Q4 2023 showed mixed results with revenue decline but sequential growth. The company is focusing on profitability improvements in 2024 and anticipates growth driven by new modalities and market recovery. Challenges in revenue performance are being addressed, with a strategic focus on key account management and cost containment.

Repligen reports mixed Q1 results, focuses on innovation and growth

Repligen's Q1 2024 performance showed mixed results with revenue declines but positive growth in key segments. The company maintains its focus on innovation, cost control, and strategic expansion while navigating challenges in profitability. Opportunities lie in market improvements and growth potential in new modalities.

Repligen reports strong Q2 performance, eyes robust growth ahead

Repligen's Q2 2024 earnings call showcased strong performance in pharma and consumables, despite challenges from China and foreign exchange. The company anticipates a return to robust revenue growth in the second half of the year and is optimistic about future growth prospects.

Repligen (RGEN) reports robust Q3 results and eyes 2025 growth

Repligen is on track to meet 2024 revenue guidance, entering 2025 in a strong position.
Exciting product launches planned for 2025 across all business units.
Strong start to Q4 with confidence in meeting financial targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Repligen (RGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 16.5% in 4 Weeks, Here's Why Repligen (RGEN) Looks Ripe for a Turnaround

WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 40th Annual J.P. Morgan Healthcare conference being held January 10-13.  Tony J. Hunt, President and Chief Executive Officer, will present on Wednesday, January 12, 2022, at 9:45 a.m. EST.

Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference

BeiGene

Sarepta Therapeutics

Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.

3 Biotech Stocks Worth Adding to Your Portfolio Next Year

Repligen (RGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Repligen (RGEN) Upgraded to Strong Buy: Here's Why

Here is how Repligen (RGEN) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.

Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?

Sets Baseline and Provides SASB, GRI Core and SDG Disclosures Sets Baseline and Provides SASB, GRI Core and SDG Disclosures

Repligen Releases Inaugural Sustainability Report

Repligen's (RGEN) third-quarter earnings and revenues beat estimates. The company raises its guidance for 2021.

Repligen (RGEN) Q3 Earnings and Sales Beat, 2021 View Up

Repligen Corporation (RGEN) CEO Anthony Hunt on Q3 2021 Results - Earnings Call Transcript

Repligen (RGEN) delivered earnings and revenue surprises of 21.88% and 8.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates

Repligen (RGEN) beats earnings and sales estimates in the third quarter of 2021.

Repligen's (RGEN) Q3 Earnings & Sales Beat Estimates

WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2021. Provided in this press release are financial highlights for the three- and nine- month periods ended September 30, 2021, updates to our financial guidance for the fiscal year 2021 and access information for today's webcast and conference call.

Repligen Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance

On Repligen's (RGEN) third-quarter earnings call, investor focus is likely to be on the sales performance of its product franchisees - filtration, chromatography, protein and process analytics.

Repligen (RGEN) to Report Q3 Earnings: What's in the Cards?

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Repligen (RGEN) Earnings Expected to Grow: Should You Buy?

Gilead Sciences

It looks like the gene therapy market is a haunted house, but growing biotech Repligen might be the treat investors need this Halloween.

2 Tricks and a Treat for Gene Therapy Investors

Webcast and Conference Call to Be Held Thursday, October 28, 2021 at 8:30 a.m. EDT

Repligen to Report Third Quarter 2021 Financial Results

The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop over the last twenty-one trading days. The company last month announced the acquisition of Avitide - a privately held.

What's Next For Repligen Stock After A 12% Fall In A Month?

Fulgent Genetics

Intuitive Surgical

It doesn't take much when you buy great companies and let them grow.

3 Unstoppable Healthcare Stocks to Buy With Just $1,000

Repligen Corporation (NASDAQ: RGEN) has agreed to acquire privately-held Avitide Inc for approximately $150 million in cash and stock. The deal consideration includes $75 million in cash plus $75 million in Repligen common stock in addition to performance-based earnout payments over the next three years.

Repligen Reinforces Proteins Business With $150M Avitide Acquisition Deal

WALTHAM, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Avitide Inc., for approximately $150 million, comprised of $75 million in cash plus $75 million in Repligen common stock in addition to performance-based earnout payments over the next three years. Avitide is a leading chromatography developer with diverse affinity ligand libraries and best-in-class ligand-to-resin development timelines.

Repligen Announces Agreement to Acquire Avitide Inc.

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), today announced they have completed development and validation of a novel protein A ligand that overcomes challenges associated with the purification of pH sensitive antibodies and Fc-fusion proteins. Named NGL-Impact ® A Hi pH, the new ligand is the first to address antibody aggregation in low pH elution buffers. While developed specifically to address pH sensitive antibodies and Fc-fusion proteins, NGL-Impact A Hi pH ligand demonstrates high performance for all antibodies, and can be considered for “platform” use due to its broad pH operating range.

Repligen and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purification of pH Sensitive Antibodies

Ralf Kuriyel, Senior VP and RD at Repligen (NASDAQ:RGEN), made a large insider sell on August 30, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Kuriyel sold 4,001 shares of Repligen at a price of $282.13 per share.

Repligen Senior VP Makes $1.13 Million Sell

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

Repligen (RGEN) Up 16.5% Since Last Earnings Report: Can It Continue?

Repligen (RGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Will Repligen (RGEN) Gain on Rising Earnings Estimates?

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

After Golden Cross, Repligen (RGEN)'s Technical Outlook is Bright

Repligen is one of those prime companies that let you sleep well at night with a long history of stable performance. The company has shown 30% revenue growth over the past decade, and will lift the trend beyond that over the next few years.

News for Repligen Stock (RGEN)